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High-affinity receptors for angiotensin II were identified on Xenoplts luevis cardiac membranes and characterized by binding-inhibition studies with 
peptide and non-peptide AI1 antagonists. Scatchard analysis of the binding data identified a high-affinity site with &, = 1.6 nM and B,,,,,, =3.7 
pmcl/mg protein and a low-affinity site with K+=22 nM and Bm;u2= 9.5 pmol/mg protein. Treatment with dithiothrcitol reduced the number of 
binding sites by > 70%. The rank order of potency for AI1 analogs was (agent, ICYSO) [Sarl.Ile~]AII. 0.91 nM > All. 2.0 nM > AI, 5.3 nM =-tsar’. 
Alas]AII, 19 nM X= CGP42I IZA, 1.2 HIM 777 DuP 753 z PD- I23 177. 7 100 pM. The relative potencies of these compounds differ markedly from 
their activities on the two known mammalian AI1 receptor subtypes, AT, and AT?. These results indicate tl:z: amphibian AI1 receptors are pharma- 
cologically distinct from both the AT, and AT2 receptors characterized in mammalian tissues. 
Angiotensin receptor: Angiotcnsin: Angiotensin xccptor antagonist; Xerloprts luevis: Myocardium: Heart 
1. INTRODUCTION 
Angiotensin II (AH)’ receptors exert a wide variety of 
effects on many tissues including the vasculature, 
adrenal, kidney, brain, liver, and heart [I]. The ex- 
istence of AI1 receptor subtypes could account for the 
diverse actions of AI1 in various target issues, and on 
cardiovascular function and sodium homeostasis. 
Receptor heterogeneity has been suggested by radio- 
ligand binding studies [2,3] and by the demonstration 
of multiple mechanisms of AI1 receptor signal trans- 
duction, including phosphoinositide turnover, inhibi- 
tion of adenylate cyclase, and Ca” channel regulation 
[3,4]. Studies employing recently developed peptide and 
non-peptide AI1 antagonists have characterized two AI1 
receptor subtypes (ATI and AT2) with identical af- 
finities for AI1 and most of its peptide antagonists [5,6]. 
A receptor that is coupled to the known cellular 
responses to AI1 is blocked by the non-pepride an- 
tagonist, DuP 753, and is defined as the ATI subtype. 
The function of the AT2 receptor, which is defined by 
the inhibition of radioligand binding by novel an- 
tagonists uch as PD-12377 and CGP 42112A, is not yet 
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known. The two subtypes are present in various propor- 
tions in different tissues; ATI sites are abundant in 
adrenal cortex and vascular tissues, and AT2 sites are 
highly enriched in uterus [6] and adrenal medulla [7], as 
well as the PC12 line of adrenal phaeochromocytoma 
cells [8]. ‘& 
We have recently observed that Xenopus faevis 
follicular oocytes contain endogenous AI1 receptors 
which are functionalIy similar to the ATI mammalian 
receptor in that they mobilize intracellular Cat+ in 
response to AI1 [9]. However, the sensitivity of AII- 
induced calcium responses in the amphibian oocyte to 
the new antagonists differed markedly from those of 
the recently-defined mammalian AI1 receptor subtypes 
[IO]. The low levels of 1251-[Sar1,11e8]AII binding in 
oocytes did not permit a detailed characterization of the 
binding parameters of AI1 receptors in oocyte mem- 
branes. For this reason, we could not rule out the ex- 
istence of amphibian oocyte AI1 receptor subtype that 
is not linked to Ca’+ mobilization. Subsequently, we 
screened several Xenopus tissues and found high levels 
of 1251-[Sar’,Iles]AII binding in the heart. In the present 
study, amphibian cardiac AI1 receptors were character- 
ized and found to be pharmacologically distinct from 
the AI1 receptor subtypes identified in mammalian 
tissues including the rabbit ventricular myocardium. 
2. MATERIALS AND METHODS 
‘l”I-[Sar’,Ilen]AII (2200 Ci/mmol) was obtnincd from New 
England Nuclear (Boston, MA). [Sar’,Alas]AII and [Sar’,llcbjAII 
were purchased from Pcninsuln Labs (Belmont, CA). All and Al 
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were obtained from Bachem Inc. (Torrance, CA). The peptide AI I an- 
tagonist, nicotinic acid-Tyr-(w-benzyloxycarbonyl-Arg)Lys-His- 
Pro-lie (CGP 421 IZA) was provided by Dr M. de Gasparo (Ciba- 
Geigy Basel. Switzerland). The non-peptide All antagonists, DuP753 
(2-n-butyl-4-chloro-5-hydroxy-methyl-l-(2’-(1H-tetrazol-5-yl)biphen- 
yl-4-yl)methyl imidazole, potassium salt) and PD-123177 (l-(4- 
amino-3-methylphenyl)methyl-5-diphenyl-acety1-4,5,6,7-tetrahydro- 
IH-imidazole[-4.5-clpyridine-6-carboxylic acid . HCI) were provided 
by Dr PC. Wong (DuPont, Wilmington, DE)‘. 
Heart tissue was removed from Xenopus kaevis (Xenopus I, Ann 
Arbor, MI) frogs and immediately homogenized with a polytron in 
ice-cold, freshly prepared 20 mM NaHCOj. The homogenate was stir- 
red on ice for 20 min and then filtered through nylon mesh. After cen- 
trifugation at 100 x g for 10 min at 4”C, the supernatant was remov- 
ed and centrifuged at 30 000 x g for 20 min at 4°C. The particulate 
fraction was washed by resuspending the pellet in homogenization 
buffer and centrifuging again at 30 000 x g for 20 min. The final 
pellet was resuspended in ice-cold binding buffer at a concentration of 
1 pg/hl for binding studies. 
Cardiac membranes (25-80 pg protein/tube) were incubated with 
‘2~1-[Sar’,lles]AII (50 PM) in 400 @I binding buffer (50 mM Tris-HCI, 
5 mM MgClr, 2 mM EGTA. 100 mM NaCI, 1.0% bovine serum 
albumin, pH 7.4) with increasing concentrations of All and an- 
tagonist ligands. The incubations were terminated after 2 h at room 
temperature by rapid filtration and the membranes were collected on 
glass fiber filters (Whatman GFC). The specific binding was defined 
as the difference between the total radioactivity bound to membranes 
and that bound in the presence of I FM unlabeled All. In typical ex- 
periments, the total binding was between IO 000 and 35 000 cpm and 
the non-specific binding was between 400 to 500 cpm. All experiments 
were performed in duplicate with a variation of less than 10% and 
were repeated 2-3 times. The binding data were analyzed using an 
iterative non-linear regression analysis computer program (‘Ligand’, 
Dr P.J. Munson, NICHD, NIH, Bethesda, MD). 
3. RESULTS 
In our previous report [lo], the amphibian oocyte 
AI1 receptor was shown to be pharmacologically 
distinct from the mammalian ATI and AT2 receptors, a 
finding that extends previous observations on dif- 
ferences in AII-related peptide agonist activities bet- 
ween amphibian and expressed mammalian AI1 recep- 
tors [9]. Because the levels of ‘251-[Sar’,Ile8]AII binding 
to oocyte membranes were too low to perform quan- 
titative receptor analysis, we screened several tissues 
from Xenoplts frogs in order to find a suitable source 
for radioligand binding studies. In autoradiographic 
studies with ‘Z51-[Sart,Ilea]AII, AI1 receptors were 
observed in skin, ovary, kidney and heart; no specific 
binding was seen in the liver, spleen or air sac (data not 
shown). We chose the heart to perform binding studies 
since ‘2SI-[Sar’,Ile6]AII binding was abundant, and 
could be directly compared with the recent characteriza- 
tion of A11 receptor subtypes in mammalian cardiac 
tissue [ 111. 
Initial experiments indicated that specific binding of 
50 pM ‘251-[Sar’,Iles]AII to Xenopus cardiac mem- 
branes reached equilibrium between 1 and 2 h at room 
temperature, and was linear between 10 and 160 pg pro- 
tein. The levels of 1251-[Sar’,Ilea]AII binding were 
higher in fresh tissue (89 f 7.0 fmol/mg protein) than in 
frozen tissue (38 ~2.3 fmol/mg protein) and were 
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reduced by 85% when incubations were performed at 
4°C. The binding of ‘2SI-[Sar’,Ile*]AII was reversible as 
evidenced by the abiIity of unlabeled AI1 to displace the 
bound peptide from membrane receptors (data not 
shown). Scatchard analysis of the equilibrium binding 
data gave curvilinear plots that were best fit by a two- 
site model (Fig. 1), giving a high-affinity site with &’ 
= 1.6f0.18 nM and B,,x, of 3.7 + 0.34 pmol/mg, and 
a low-affinity site with KdZ = 22 + 2.5 nM and Bmax2 = 
9.5+ 1.0 pmol/mg. These data are consistent with 
reports of two classes of binding sites in mammalian 
heart membranes [12,13]. The two sites identified by 
Scatchard analysis could represent two distinct AI1 
receptors, or could reflect the existence of one AI1 
receptor in different affinity states. In this regard, 
mammalian high-affinity AI1 receptors are well known 
to be regulated by guanine nucleotides [4,12,13]. 
The recent development of several novel AiI receptor 
antagonists has permitted the characterization in 
several tissues of two AI1 receptor subtypes, AT’ and 
ATI, which have identical affinity for AI1 and the ma- 
jority of its peptide analogs. AT’ and AT2 receptors are 
differentially affected by dithiothreitol, which inhibits 
ATI receptor binding but enhances AT2 receptor bin- 
ding [IO]. In amphibian cardiac receptors, DTT 
markedly reduced the binding of ‘2sI-[Sar’,Iles]AII. 
Scatchard analysis revealed that DTT reduced the &,,,, 
of both binding sites but only marginally affected bin- 
ding affinities (&, = 1.2 + 0.19 nM, Bmaxl = 2.9 f 0.35 
fmol/mg; &2 = 18t2.1 nM, Bmnx2 = 2.8kO.38 
pmol/mg). 
The major mammalian AI1 receptor subtype, ATI, 
which appears to mediate all physiological responses so 
far studied, binds DuP 753 with high affinity (Ki = 
25-60 nM) but does not recognize PD-123177. CGP 
42112A is a weak antagonist (Ki = 0.6-3.7 FM) at this 
receptor, in contrast to its high affinity (Ki = 0. l-l nM) 
for the AT2 receptor [6,11]. The AT2 receptor also 
binds PD 123177 (ICSO = 3 nM) but does not recognize 
BOUND (nM) 
Fig, I. Rorcnthal plot of ‘z51-[Sar’,llcR]AII binding to Xcvtuprts car- 
diac mcmbrancs. The binding data arc rcprcscntativeof 3 competition 
experiments performed in duplicate (see Fig. 2) analyzing using an 
itcrntivc non-linear rcgrcssion analysis computer program (see section 
2). Mcmbranc protein content \vas 25 /1g/tubc, 
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Fig, 2. Competitive inhibition of “‘I-[Sar’,llc”]AII binding to 
Xt~op~s cardiac membranes. The competition curves are represen- 
tative of 3 experiments performed in duplicate. The unlabclcd ligands 
used were [Sar’,lle”]All (e 1, All (o), AI (o), [Sar’,Ala’]AIl (A), 
CGP 42112A (o), PD-123177 ( A ) and DuP 753 (m). Membrane pro- 
tein content was 25 Gg/tube. Total and non-specific binding ranged 
between 10 to 15 000 cpm and 400-500 cpm, respectively. 
DuP 753 [S,7,8]. The rank order of potency of the 
several AI1 agonist and antagonist compounds in 
Xenopuscardiac muscle was [Sar’,IIeS]AI1 > AI1 > AI 
> [Sar’,Ala’]AII > > CGP 42112A; the non-peptide 
antagonists, DuP 753 and PD-123177, did not compete 
with ‘2SI-[Sar’,Ile8]AII binding at micromolar concen- 
trations (Fig. 2, Table I). Computer-assisted analysis of 
the binding data demonstrated that none of the peptide 
antagonists could be fit to a single site model which is 
consistent with the two classes of AI1 binding sites 
revealed by Scatchard analysis (Fig. 1). 
:, 
4. DISCUSSION 
The characterization of Xertopus myocardial AI1 
receptors has revealed distinct pharmacological dif- 
ferences between amphibian and mammalian cardiac 
receptors. While the amphibian ovarian AI1 receptor is 
functionally similar to the mammalian ATI receptor in 
terms of Ca2’ mobilization, it is almost unaffected by 
the non-peptide AI1 receptor antagonist, DuP 753, 
Table I 
Inhibition constants for binding of AI1 agonists and antagonists to 
XCIIO/IU.S myocardial membranes 
Agent IC.cU 
[Sar’,llcR]AII 0.91 k 0.084 nM 
Angiorcnsin II 2.0 ? 0. Ih nhl 
Angiotensin I 5.3 k O,S7 nM 
[Snr’,Ala”]All 19 r 2.2 nhl 
C’GP-42 1 IZA 1.2 k O,l3 /rkl 
DuP 753 > 100 ,Ihl 
I’D-123177 > 100 ,Ihl 
lCr0 is dcfincd as lhc concentration at which 5OYo of the maximum 
binding of “‘1 [Snr’,llc”]All is inhibitctl nntl iT c:~lculu~cd by com- 
puter analysis from 3 cxpcrimcnts performed in duplicntc. 
which selectively binds to mammalian ATI receptors 
[S,7]. In the present binding study, we found that 
Xenopus cardiac AI1 receptors do not recognize either 
DuP 743 or PD-123177, an antagonist which specifical- 
ly binds to the mammalian AT2 receptor [S,7,8]. Fur- 
thermore, CGP-42112A is three orders of magnitude 
less potent than AI1 in amphibian cardiac tissue, in con- 
trast to its equipotency at the mammalian AT2 receptor 
[6, Ill. In Xenopus myocardium, AI1 was twofold more 
potent than AI, in contrast to mammalian tissue where 
AI1 is 2-3 orders of magnitude more potent than AI 
[ 13- 1 S] I However, the relatively higher potency of AI in 
the amphibian heart might reflect its conversion to the 
octapeptide agonist during incubation for the binding 
assay. 
These results extend our previous observations on the 
pharmacoiogical difference between functional 
responses mediated by amphibian AI1 receptors and 
mammalian AI1 receptors expressed in Xenopus 
oocytes [9,10]. Since AI1 receptor subtypes have not 
been characterized in the mammalian ovary, we could 
not rule out the possibility of tissue-specific differences. 
In this study, we could directly compare our binding 
data in frog heart with the AI1 receptor subtypes recent- 
ly characterized in the rabbit heart [l I]. In that report, 
ATI receptors, which recognized DuP 753 with much 
higher affinity than CGP 42112A and with one order of 
magnitude less affinity than AIL itself, composed about 
33% of the total AI1 receptor population. AT2 recep- 
tors, at which CGP 42112A was equipotent with AI1 
and showed fivefold higher affinity than DuP 753, 
comprised the remaining 67%. DTT was shown to 
strongly inhibit the ATI receptor and to markedly 
enhance AI1 binding to the AT2 receptor. In contrast, 
the amphibian heart AI1 receptor does not behave like 
either of the mammalian cardiac receptor subtypes. It 
does not recognize DuP 753, unlike the mammalian 
ATI receptor. Also, it does not behave like the AT2 
receptor since AI1 exhibits three orders of magnitude 
higher affinity for amphibian receptor than CGP 
42112A, and because DTT dramatically reduces AI1 
binding rather than enhancing it. These results 
demonstrate that AI1 receptors in Xerlopus laevis and 
mammalian cardiac muscle are pharmacologically 
distinct in their binding affinities for novel peptide and 
non-peptide antagonists, consistent with molecular 
heterogeneity of the AI1 receptors and evolutionary dif- 
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